{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Tumors&page=2", "query": { "condition": "Malignant Tumors", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Tumors&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T12:15:50.786Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05983133", "title": "A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Squamous Cell Carcinoma of the Head and Neck", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "PF-08046052", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2023-11-14", "completion_date": "2026-04-16", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-06-11T12:15:50.786Z", "location_count": 22, "location_summary": "Los Angeles, California • Santa Monica, California • Tampa, Florida + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05983133" }, { "nct_id": "NCT00003789", "title": "Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Recurrent Melanoma", "Stage III Melanoma" ], "interventions": [ { "name": "isolated limb perfusion", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "recombinant tumor necrosis factor family protein", "type": "BIOLOGICAL" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 216, "start_date": "1999-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-07-16", "last_synced_at": "2026-06-11T12:15:50.786Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003789" }, { "nct_id": "NCT01870609", "title": "Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Pleural Mesothelioma" ], "interventions": [ { "name": "defactinib (VS-6063)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Verastem, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 344, "start_date": "2013-09", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2017-01-30", "last_synced_at": "2026-06-11T12:15:50.786Z", "location_count": 12, "location_summary": "San Francisco, California • Weston, Florida • Chicago, Illinois + 9 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Weston", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01870609" }, { "nct_id": "NCT00002909", "title": "Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "chemotherapy", "type": "DRUG" }, { "name": "oral sodium phenylbutyrate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "1997-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-05", "last_synced_at": "2026-06-11T12:15:50.786Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002909" }, { "nct_id": "NCT02010606", "title": "Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme", "Glioma", "Astrocytoma", "Brain Tumor" ], "interventions": [ { "name": "Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy", "type": "BIOLOGICAL" }, { "name": "Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2014-01-08", "completion_date": "2021-07-10", "has_results": false, "last_update_posted_date": "2021-11-22", "last_synced_at": "2026-06-11T12:15:50.786Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02010606" }, { "nct_id": "NCT04420884", "title": "A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Neoplasms" ], "interventions": [ { "name": "Dazostinag", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Platinum", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 248, "start_date": "2020-07-22", "completion_date": "2026-03-30", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-06-11T12:15:50.786Z", "location_count": 26, "location_summary": "La Jolla, California • Los Angeles, California • Orange, California + 20 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04420884" }, { "nct_id": "NCT02043184", "title": "Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Prostatic Neoplasms", "Breast Neoplasms", "Colorectal Neoplasms", "Melanoma", "Leukemia" ], "interventions": [ { "name": "Interactive Voice Response (IVR) Reminders", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Michigan State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 322, "start_date": "2013-03", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2017-06-07", "last_synced_at": "2026-06-11T12:15:50.786Z", "location_count": 8, "location_summary": "New Haven, Connecticut • Chicago, Illinois • Indianapolis, Indiana + 4 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02043184" }, { "nct_id": "NCT05384626", "title": "A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Solid Tumor" ], "interventions": [ { "name": "Neladalkib (NVL-655)", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvalent Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 840, "start_date": "2022-06-09", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-06-11T12:15:50.786Z", "location_count": 21, "location_summary": "Orange, California • Sacramento, California • Stanford, California + 16 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05384626" }, { "nct_id": "NCT06172478", "title": "A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Melanoma", "Head and Neck Cancer", "Gastric Cancer", "Ovarian Carcinoma", "Cervical Cancer", "Endometrial Cancer", "Bladder Cancer", "Esophageal Cancer", "Pancreatic Carcinoma", "Prostate Cancer", "Non-small Cell Lung Cancer (NSCLC)", "Lung Cancer", "Breast Cancer" ], "interventions": [ { "name": "HER3-DXd", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 740, "start_date": "2024-02-26", "completion_date": "2028-10-10", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-06-11T12:15:50.786Z", "location_count": 13, "location_summary": "Duarte, California • New Haven, Connecticut • Kissimmee, Florida + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Kissimmee", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06172478" }, { "nct_id": "NCT05297565", "title": "A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Nivolumab/rHuPH20", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2022-08-02", "completion_date": "2024-02-08", "has_results": true, "last_update_posted_date": "2025-02-27", "last_synced_at": "2026-06-11T12:15:50.786Z", "location_count": 2, "location_summary": "Fort Wayne, Indiana • Knoxville, Tennessee", "locations": [ { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05297565" } ] }